Cargando…

Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor

BACKGROUND: SARS-CoV-2 causes COVID-19 which has a widely diverse disease profile. The mechanisms underlying its pathogenicity remain unclear. We set out to identify the SARS-CoV-2 pathogenic proteins that through host interactions cause the cellular damages underlying COVID-19 symptomatology. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jin-Gu, Huang, Weiliang, Lee, Hangnoh, van de Leemput, Joyce, Kane, Maureen A., Han, Zhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993076/ https://www.ncbi.nlm.nih.gov/pubmed/33766124 http://dx.doi.org/10.1186/s13578-021-00568-7

Ejemplares similares

Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment
por: Zhu, Jun-yi, et al.
Publicado: (2021)

SARS-CoV-2 Nsp6 damages Drosophila heart and mouse cardiomyocytes through MGA/MAX complex-mediated increased glycolysis
por: Zhu, Jun-yi, et al.
Publicado: (2022)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
por: Stiff, Patrick J., et al.
Publicado: (2023)

Drosophila, a powerful model to study virus-host interactions and pathogenicity in the fight against SARS-CoV-2
por: van de Leemput, Joyce, et al.
Publicado: (2021)

H3K36 Di-Methylation Marks, Mediated by Ash1 in Complex with Caf1-55 and MRG15, Are Required during Drosophila Heart Development
por: Zhu, Jun-yi, et al.
Publicado: (2023)

Selinexor for multiple myeloma
Publicado: (2022)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Selinexor and COVID-19: The Neglected Warden
por: Mostafa-Hedeab, Gomaa, et al.
Publicado: (2022)

Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19
por: van de Leemput, Joyce, et al.
Publicado: (2021)

Combining selinexor with alisertib to target the p53 pathway in neuroblastoma
por: Nguyen, Rosa, et al.
Publicado: (2022)

Changes in Subcellular Localization of Host Proteins Induced by Plant Viruses
por: Rodriguez-Peña, Rosalba, et al.
Publicado: (2021)

Subcellular Localization of SARS-CoV Structural Proteins
por: Lopez, Lisa A., et al.
Publicado: (2006)

A putative diacidic motif in the SARS-CoV ORF6 protein influences its subcellular localization and suppression of expression of co-transfected expression constructs
por: Gunalan, Vithiagaran, et al.
Publicado: (2011)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

Selinexor: Targeting a novel pathway in multiple myeloma
por: Mo, Clifton C., et al.
Publicado: (2023)

UPLC-MS/MS Measurement of the Effect of Isavuconazole, Itraconazole and Fluconazole on the Pharmacokinetics of Selinexor in Rats
por: Li, Shuang-long, et al.
Publicado: (2020)

PsORF: a database of small ORFs in plants
por: Chen, Yanjun, et al.
Publicado: (2020)

Predicting the subcellular localization of viral proteins within a mammalian host cell
por: Scott, MS, et al.
Publicado: (2006)

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
por: Garg, Manoj, et al.
Publicado: (2016)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

Clinical characteristics and host immunity responses of SARS-CoV-2 Omicron variant BA.2 with deletion of ORF7a, ORF7b and ORF8
por: Tang, Zhizhong, et al.
Publicado: (2023)

Refining Protein Subcellular Localization
por: Scott, Michelle S, et al.
Publicado: (2005)

Study of PTEN subcellular localization
por: Bononi, Angela, et al.
Publicado: (2015)

Modelling of pathogen-host systems using deeper ORF annotations and transcriptomics to inform proteomics analyses
por: Leblanc, Sebastien, et al.
Publicado: (2020)

US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
por: Bassali, Jan, et al.
Publicado: (2020)

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Subcellular localization and membrane association of SARS-CoV 3a protein
por: Yuan, Xiaoling, et al.
Publicado: (2005)

Fluorescence resonance energy transfer (FRET)-based subcellular visualization of pathogen-induced host receptor signaling
por: Buntru, Alexander, et al.
Publicado: (2009)

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
por: Mateos, Maria V., et al.
Publicado: (2021)

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
por: Lassman, Andrew B., et al.
Publicado: (2022)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
por: Gounder, Mrinal, et al.
Publicado: (2021)

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
por: Klement, Piroska, et al.
Publicado: (2022)

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia
por: Vitale, Candida, et al.
Publicado: (2023)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
por: Zhong, Yuping, et al.
Publicado: (2023)

The distribution, abundance and subcellular localization of kinesin
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_cr34g00rnvsah4dfitfs8d4d0h